JP2018512373A - Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 - Google Patents

Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 Download PDF

Info

Publication number
JP2018512373A
JP2018512373A JP2017534275A JP2017534275A JP2018512373A JP 2018512373 A JP2018512373 A JP 2018512373A JP 2017534275 A JP2017534275 A JP 2017534275A JP 2017534275 A JP2017534275 A JP 2017534275A JP 2018512373 A JP2018512373 A JP 2018512373A
Authority
JP
Japan
Prior art keywords
gst
cancer
sirna
tumor
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534275A
Other languages
English (en)
Japanese (ja)
Inventor
イン，ウェンビン
憲二郎 味呑
憲二郎 味呑
マジェッティ，バラット
ワン，リー
リュー，ジーフア
アダミ，ロジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of JP2018512373A publication Critical patent/JP2018512373A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
JP2017534275A 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 Pending JP2018512373A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014266198 2014-12-26
JP2014266198 2014-12-26
US201562184204P 2015-06-24 2015-06-24
US62/184,204 2015-06-24
US201562266672P 2015-12-13 2015-12-13
US62/266,672 2015-12-13
PCT/US2015/067559 WO2016106404A2 (en) 2014-12-26 2015-12-28 Methods and compositions for treating malignant tumors associated with kras mutation

Publications (1)

Publication Number Publication Date
JP2018512373A true JP2018512373A (ja) 2018-05-17

Family

ID=56151549

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Country Status (10)

Country Link
US (14) US10264976B2 (enExample)
EP (9) EP3236975A4 (enExample)
JP (10) JP2018512373A (enExample)
KR (4) KR20170098929A (enExample)
CN (7) CN107106564A (enExample)
AU (4) AU2015369596A1 (enExample)
BR (2) BR112017013597B1 (enExample)
CA (4) CA2972265A1 (enExample)
RU (4) RU2719185C2 (enExample)
WO (7) WO2016106405A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018512110A (ja) * 2014-12-26 2018-05-17 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2018183163A (ja) * 2014-12-26 2018-11-22 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
JP2022512077A (ja) * 2018-11-16 2022-02-02 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2016210190A1 (en) 2015-06-24 2016-12-29 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
CN108367022A (zh) * 2015-12-13 2018-08-03 日东电工株式会社 具有高活性和降低脱靶的sirna结构
TWI780046B (zh) 2016-05-10 2022-10-11 國立大學法人東京醫科齒科大學 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法
WO2018151840A2 (en) * 2017-02-16 2018-08-23 Nitto Denko Corporation Methods and compositions for treating malignant tumors
CN111386105B (zh) * 2017-11-06 2023-09-15 日东电工株式会社 用于递送生物活性分子的膜融合化合物
JP7376873B2 (ja) * 2017-11-09 2023-11-09 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
CN109777798A (zh) * 2017-11-13 2019-05-21 深圳华大生命科学研究院 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN108486011B (zh) * 2018-03-27 2020-05-05 山东大学 一种三联苯化合物、制备方法及其应用
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020009189A1 (ja) * 2018-07-05 2020-01-09 洋司郎 新津 Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
EP3851125A4 (en) * 2018-08-22 2022-08-17 Nitto Denko Corporation AGENT WITH HSP47 INHIBITOR FOR SUPPRESSING METASTASIS
JP7453145B2 (ja) * 2018-08-22 2024-03-19 日東電工株式会社 Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子
WO2020145350A1 (ja) 2019-01-10 2020-07-16 国立大学法人大阪大学 免疫賦活用組成物
JPWO2020196736A1 (enExample) * 2019-03-28 2020-10-01
JP2019116507A (ja) * 2019-04-25 2019-07-18 有限会社オービット Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
JP7692829B2 (ja) * 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
EP4090744A4 (en) * 2020-01-17 2024-04-10 Anastasia Khvorova UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS
US12534724B2 (en) 2020-05-26 2026-01-27 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN112280800B (zh) * 2020-10-19 2022-06-07 上海市东方医院（同济大学附属东方医院） 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用
AU2021416356B2 (en) 2020-12-28 2026-02-26 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
WO2022144882A2 (en) * 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna target areas for silencing
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
US20250290076A1 (en) * 2022-04-27 2025-09-18 Kyoto University Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration
WO2025072649A1 (en) * 2023-09-28 2025-04-03 Nitto Denko Corporation Combination therapy

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88550A (pt) 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas
US5204241A (en) 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
CA2221568C (en) 1995-06-07 2010-05-04 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
JPH10330249A (ja) * 1997-05-30 1998-12-15 Kureha Chem Ind Co Ltd レチノール化合物含有ｈｓｐ４７合成抑制剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP4059627B2 (ja) 1998-04-16 2008-03-12 帝人株式会社 グルタチオン誘導体とその投与形態
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070083945A1 (en) * 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
WO2001088191A1 (en) * 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
AU2004266311B2 (en) 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2004055165A2 (en) * 2002-12-13 2004-07-01 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2322650A1 (en) * 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
DK2386640T3 (en) * 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
EP4005601A1 (en) 2004-12-22 2022-06-01 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2008536874A (ja) 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
ES2324128A1 (es) * 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
WO2007049955A1 (en) 2005-10-25 2007-05-03 Het Nederlands Kanker Instituut Prediction of local recurrence of breast cancer
CA2627585A1 (en) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US8148086B2 (en) 2005-11-17 2012-04-03 Children's Medical Center Corporatioin Methods to predict and prevent resistance to taxoid compounds
US7729737B2 (en) 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
CA2631677C (en) 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
EP2194128B1 (en) * 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
US8067390B2 (en) 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP5558346B2 (ja) 2007-07-05 2014-07-23 ノバルティス アーゲー ウイルス感染を処置するためのｄｓＲＮＡ
DK2193140T3 (en) 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
WO2009033284A1 (en) 2007-09-14 2009-03-19 Mcmaster University Inhibitors of collagen biosynthesis as anti-tumor agents
JP2011513342A (ja) * 2008-03-06 2011-04-28 ロッタファルム・ソシエタ・ペル・アチオニ 関節炎、癌および関連疼痛の治療のための２−アリールおよび２−ヘテロアリール４ｈ−１−ベンゾピラン−４−オン−６−アミジノ誘導体
WO2010011895A1 (en) 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US20100028416A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011072082A2 (en) 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
CA2828201A1 (en) 2010-02-24 2011-09-01 Bodysync, Inc. Methods for determining gene-nutrient interactions
WO2011112954A1 (en) * 2010-03-12 2011-09-15 The Wistar Institute Inhibition of p21 and use thereof for inducing tissue regeneration
US8372819B2 (en) 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2011138786A2 (en) 2010-05-06 2011-11-10 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
EP2621502A4 (en) * 2010-09-30 2014-08-13 Nitto Denko Corp MODULATION OF TIMP1 AND TIMP2 EXPRESSION
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
AU2012267467B8 (en) 2011-06-08 2017-06-15 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
WO2012176282A1 (ja) 2011-06-21 2012-12-27 日東電工株式会社 アポトーシス誘導剤
CN102896619B (zh) * 2011-07-26 2015-04-22 苏州宝时得电动工具有限公司 动力工具及其操作方法
WO2013066485A2 (en) * 2011-08-31 2013-05-10 Asea Alexzander A Compositions and methods for treatment of metastatic cancer
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CA2856117A1 (en) * 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
EP3424511A1 (en) * 2012-05-16 2019-01-09 Aadigen, LLC Multi-target modulation for treating fibrosis and inflammatory conditions
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US9907828B2 (en) 2012-06-22 2018-03-06 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
JP2015524385A (ja) * 2012-07-02 2015-08-24 フィブロスタティン，エス．エル． Ｇｐｂｐ−１阻害およびその治療的使用
CA2879683C (en) 2012-08-03 2023-02-14 Alnylam Pharmaceuticals, Inc. Modified rnai agents
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
CN103695421B (zh) * 2013-12-09 2016-06-15 浙江大学 一种特异抑制p21基因表达的siRNA及其应用
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
CN113577290B (zh) * 2014-12-26 2023-10-24 日东电工株式会社 细胞死亡诱导试剂、细胞增殖抑制试剂及用于治疗由细胞增殖异常导致的疾病的医药组合物
CN108367022A (zh) * 2015-12-13 2018-08-03 日东电工株式会社 具有高活性和降低脱靶的sirna结构
JP6899201B2 (ja) 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022036954A (ja) * 2014-12-26 2022-03-08 日東電工株式会社 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2018183163A (ja) * 2014-12-26 2018-11-22 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2019187438A (ja) * 2014-12-26 2019-10-31 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2021006030A (ja) * 2014-12-26 2021-01-21 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
JP2018512110A (ja) * 2014-12-26 2018-05-17 日東電工株式会社 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
USRE49431E1 (en) 2014-12-26 2023-02-28 Nitto Denko Corporation RNA interference agents for GST-PI gene modulation
JP7307137B2 (ja) 2014-12-26 2023-07-11 日東電工株式会社 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2022512077A (ja) * 2018-11-16 2022-02-02 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
JP2023093769A (ja) * 2018-11-16 2023-07-04 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
US11708575B2 (en) 2018-11-16 2023-07-25 Nitto Denko Corporation RNA interference delivery formulation and methods for malignant tumors
TWI840449B (zh) * 2018-11-16 2024-05-01 日商日東電工股份有限公司 用於惡性腫瘤之rna干擾輸送配方及方法
JP7667077B2 (ja) 2018-11-16 2025-04-22 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法

Also Published As

Publication number Publication date
EP3236976A1 (en) 2017-11-01
EP3236976A4 (en) 2018-10-31
RU2017126610A (ru) 2019-01-28
US10047110B2 (en) 2018-08-14
JP6793649B2 (ja) 2020-12-02
WO2016106401A2 (en) 2016-06-30
BR112017013597B1 (pt) 2024-01-16
USRE49431E1 (en) 2023-02-28
JP2018512060A (ja) 2018-05-10
WO2016106400A3 (en) 2016-09-01
US20160186182A1 (en) 2016-06-30
KR20170093988A (ko) 2017-08-16
WO2016106403A2 (en) 2016-06-30
AU2015369596A1 (en) 2017-07-27
US9580710B2 (en) 2017-02-28
US20160208265A1 (en) 2016-07-21
RU2017126613A3 (enExample) 2019-06-05
US20160208255A1 (en) 2016-07-21
JP6457645B2 (ja) 2019-01-23
CN107106592A (zh) 2017-08-29
EP3236945B1 (en) 2021-02-17
CN107106591A (zh) 2017-08-29
WO2016106406A3 (en) 2016-11-03
WO2016106403A3 (en) 2016-08-18
US20160208256A1 (en) 2016-07-21
RU2017126601A (ru) 2019-01-28
RU2017126613A (ru) 2019-01-28
EP3236945A4 (en) 2018-09-12
EP3236945A2 (en) 2017-11-01
CN107108686B (zh) 2021-07-16
US20160376296A1 (en) 2016-12-29
EP3236975A2 (en) 2017-11-01
US20220087531A1 (en) 2022-03-24
CA2971881A1 (en) 2016-06-30
WO2016106402A1 (en) 2016-06-30
KR102527430B1 (ko) 2023-05-02
AU2015369595A1 (en) 2017-07-27
CA2972265A1 (en) 2016-06-30
US10047111B2 (en) 2018-08-14
JP2018512110A (ja) 2018-05-17
WO2016106404A2 (en) 2016-06-30
EP3236969A2 (en) 2017-11-01
KR20170098929A (ko) 2017-08-30
EP3236976B1 (en) 2021-07-21
EP3240796A4 (en) 2018-08-08
US9771582B2 (en) 2017-09-26
JP7655971B2 (ja) 2025-04-02
JP2025102833A (ja) 2025-07-08
EP3236974B1 (en) 2020-02-26
RU2017126610A3 (enExample) 2019-07-17
US20160208254A1 (en) 2016-07-21
EP3236969A4 (en) 2018-06-13
KR20170100010A (ko) 2017-09-01
US20160186183A1 (en) 2016-06-30
EP3236975A4 (en) 2018-09-12
WO2016106401A3 (en) 2016-09-15
CA2972270A1 (en) 2016-06-30
AU2015369592A1 (en) 2017-08-10
CN108064153A (zh) 2018-05-22
WO2016106406A2 (en) 2016-06-30
KR20170096199A (ko) 2017-08-23
JP2022036954A (ja) 2022-03-08
JP6730285B2 (ja) 2020-07-29
USRE48887E1 (en) 2022-01-11
CA2972268A1 (en) 2016-06-30
US10405749B2 (en) 2019-09-10
AU2015369592B2 (en) 2021-05-06
US20160215286A1 (en) 2016-07-28
US9695206B2 (en) 2017-07-04
EP3236973A2 (en) 2017-11-01
JP7307137B2 (ja) 2023-07-11
EP3683309A1 (en) 2020-07-22
BR112017013597A2 (pt) 2018-03-06
JP2023123743A (ja) 2023-09-05
EP3236973A4 (en) 2018-09-12
CN108024961A (zh) 2018-05-11
JP2018513104A (ja) 2018-05-24
WO2016106400A2 (en) 2016-06-30
EP3240796B1 (en) 2020-12-16
JP2018513668A (ja) 2018-05-31
RU2756253C2 (ru) 2021-09-28
EP3236974B9 (en) 2020-08-05
EP3798308A1 (en) 2021-03-31
US10023597B2 (en) 2018-07-17
JP2018512041A (ja) 2018-05-10
US20170218365A1 (en) 2017-08-03
CN107108686A (zh) 2017-08-29
US20170298086A1 (en) 2017-10-19
CN107106591B (zh) 2020-09-01
EP3236974A2 (en) 2017-11-01
USRE49229E1 (en) 2022-10-04
EP3240796A1 (en) 2017-11-08
RU2719185C2 (ru) 2020-04-17
RU2017126598A (ru) 2019-01-28
CA2971881C (en) 2023-04-04
JP2018513669A (ja) 2018-05-31
CN107106592B (zh) 2021-04-27
WO2016106405A1 (en) 2016-06-30
US10264976B2 (en) 2019-04-23
WO2016106404A3 (en) 2016-09-15
CN108064155B (zh) 2021-06-08
BR112017013599A2 (pt) 2018-03-06
JP6865169B2 (ja) 2021-04-28
CN108064155A (zh) 2018-05-22
AU2015369598A1 (en) 2017-07-27
EP3236974A4 (en) 2018-06-13
CN107106564A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
USRE49229E1 (en) Methods and compositions for treating malignant tumors associated with KRAS mutation
US10792299B2 (en) Methods and compositions for treating malignant tumors associated with kras mutation
JP6457704B2 (ja) 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
US11352628B2 (en) Methods and compositions for treating malignant tumors associated with KRAS mutation
CN103380214B (zh) 用于治疗脑肿瘤的支链氨基转移酶-1(bcat1)抑制剂
JP2019033741A (ja) 悪性腫瘍に対する治療方法及び治療用組成物
US20220275373A1 (en) Methods and compositions for treating malignant tumors associated with kras mutation
JP6978561B2 (ja) ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
TW201717969A (zh) 用於治療與ｋｒａｓ突變相關之惡性腫瘤的方法與組成物
US20180369274A1 (en) Rna interference agents for gst-pi gene modulation
HK1245674B (en) Rna interference agents for gst-pi gene modulation

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20171121